Univariate and multivariate analyses of factors influencing OS among patients transplanted in CR1, according to donor type
| Covariates . | Related (n = 310) . | Unrelated (n = 331) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N . | Univariate . | Multivariate . | N . | Univariate . | Multivariate . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| WBC count at diagnosis | ||||||||||
| < 30 000/μL | 224 | 1.00 | — | 230 | 1.00 | — | ||||
| 30 000/μL or more at diagnosis | 86 | 1.19 (0.78-1.82) | .42 | — | 101 | 0.83 (0.56-1.25) | .38 | — | ||
| Lineage | ||||||||||
| B | 218 | 1.00 | — | 203 | 1.00 | — | ||||
| T | 50 | 0.73 (0.34-1.77) | .52 | — | 54 | 0.81 (0.44-1.48) | .35 | — | ||
| Other | 42 | 0.94 (0.54-1.64) | .84 | — | 74 | 1.08 (0.70-1.67) | .72 | — | ||
| Karyotype | ||||||||||
| Normal | 193 | 1.00 | — | 208 | 1.00 | — | ||||
| t(4;11) or t(1;19) | 21 | 0.51 (0.14-1.54) | .19 | — | 11 | 1.49 (0.54-4.09) | .44 | 1.59 (0.58-4.36) | .37 | |
| Other (no t(9;22)) | 96 | 1.03 (0.67-7.14) | .89 | — | 112 | 1.49 (1.03-2.17) | .04 | 1.43 (1.13-2.40) | .01 | |
| JALSG risk stratification | ||||||||||
| Low | 39 | 1.00 | — | 45 | 1.00 | — | ||||
| Intermediate | 163 | 1.36 (0.87-2.12) | .18 | — | 192 | 1.06 (0.71-1.59) | .77 | — | ||
| High | 108 | 1.77 (0.95-3.31) | .07 | — | 94 | 1.02 (0.56-1.88) | .94 | — | ||
| Age at allo-SCT | ||||||||||
| < 45 y old | 255 | 1.00 | — | 281 | 1.00 | — | ||||
| 45 y old or older at allo-SCT | 55 | 2.04 (1.30-3.13) | .002 | 2.13 (1.36-3.34) | .0009 | 50 | 1.05 (0.63-1.73) | .86 | ||
| HLA | ||||||||||
| Match | 285 | 1.00 | — | 192 | 1.00 | — | ||||
| Mismatch | 25 | 0.95 (0.46-1.96) | .90 | — | 139 | 1.44 (1.01-2.06) | .04 | 1.45 (1.01-2.07) | .04 | |
| Stem cell source | ||||||||||
| Bone marrow | 212 | 1.00 | — | — | ||||||
| Peripheral blood | 98 | 1.43 (0.94-2.13) | .09 | 1.40 (0.93-2.11) | .11 | |||||
| Time from diagnosis to allo-SCT | ||||||||||
| 6 mo or longer | 169 | 1.00 | — | 23 | 1.00 | — | ||||
| < 6 mo | 141 | 1.75 (1.16-2.63) | .007 | 1.80 (1.19-2.71) | .005 | 308 | 0.33 (0.10-1.04) | .06 | — | |
| < 10 mo | 278 | 1.00 | — | 166 | 1.00 | — | ||||
| 10 mo or longer | 32 | 0.56 (0.26-1.20) | .14 | — | 165 | 1.54 (1.07-2.21) | .02 | 1.62 (1.12-2.34) | .01 | |
| Preparative regimen | ||||||||||
| Non-TBI regimens | 25 | 1.00 | — | 12 | 1.00 | — | ||||
| TBI regimens | 285 | 0.72 (0.38-1.35) | .30 | — | 319 | 0.59 (0.27-1.26) | .17 | — | ||
| GVHD prophylaxis | ||||||||||
| Cyclosporine A with or without other | 283 | 1.00 | — | 171 | 1.00 | — | ||||
| Tacrolimus with or without other | 27 | 2.02 (1.15-3.56) | .01 | — | 160 | 1.38 (0.96-1.97) | .08 | — | ||
| Covariates . | Related (n = 310) . | Unrelated (n = 331) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N . | Univariate . | Multivariate . | N . | Univariate . | Multivariate . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| WBC count at diagnosis | ||||||||||
| < 30 000/μL | 224 | 1.00 | — | 230 | 1.00 | — | ||||
| 30 000/μL or more at diagnosis | 86 | 1.19 (0.78-1.82) | .42 | — | 101 | 0.83 (0.56-1.25) | .38 | — | ||
| Lineage | ||||||||||
| B | 218 | 1.00 | — | 203 | 1.00 | — | ||||
| T | 50 | 0.73 (0.34-1.77) | .52 | — | 54 | 0.81 (0.44-1.48) | .35 | — | ||
| Other | 42 | 0.94 (0.54-1.64) | .84 | — | 74 | 1.08 (0.70-1.67) | .72 | — | ||
| Karyotype | ||||||||||
| Normal | 193 | 1.00 | — | 208 | 1.00 | — | ||||
| t(4;11) or t(1;19) | 21 | 0.51 (0.14-1.54) | .19 | — | 11 | 1.49 (0.54-4.09) | .44 | 1.59 (0.58-4.36) | .37 | |
| Other (no t(9;22)) | 96 | 1.03 (0.67-7.14) | .89 | — | 112 | 1.49 (1.03-2.17) | .04 | 1.43 (1.13-2.40) | .01 | |
| JALSG risk stratification | ||||||||||
| Low | 39 | 1.00 | — | 45 | 1.00 | — | ||||
| Intermediate | 163 | 1.36 (0.87-2.12) | .18 | — | 192 | 1.06 (0.71-1.59) | .77 | — | ||
| High | 108 | 1.77 (0.95-3.31) | .07 | — | 94 | 1.02 (0.56-1.88) | .94 | — | ||
| Age at allo-SCT | ||||||||||
| < 45 y old | 255 | 1.00 | — | 281 | 1.00 | — | ||||
| 45 y old or older at allo-SCT | 55 | 2.04 (1.30-3.13) | .002 | 2.13 (1.36-3.34) | .0009 | 50 | 1.05 (0.63-1.73) | .86 | ||
| HLA | ||||||||||
| Match | 285 | 1.00 | — | 192 | 1.00 | — | ||||
| Mismatch | 25 | 0.95 (0.46-1.96) | .90 | — | 139 | 1.44 (1.01-2.06) | .04 | 1.45 (1.01-2.07) | .04 | |
| Stem cell source | ||||||||||
| Bone marrow | 212 | 1.00 | — | — | ||||||
| Peripheral blood | 98 | 1.43 (0.94-2.13) | .09 | 1.40 (0.93-2.11) | .11 | |||||
| Time from diagnosis to allo-SCT | ||||||||||
| 6 mo or longer | 169 | 1.00 | — | 23 | 1.00 | — | ||||
| < 6 mo | 141 | 1.75 (1.16-2.63) | .007 | 1.80 (1.19-2.71) | .005 | 308 | 0.33 (0.10-1.04) | .06 | — | |
| < 10 mo | 278 | 1.00 | — | 166 | 1.00 | — | ||||
| 10 mo or longer | 32 | 0.56 (0.26-1.20) | .14 | — | 165 | 1.54 (1.07-2.21) | .02 | 1.62 (1.12-2.34) | .01 | |
| Preparative regimen | ||||||||||
| Non-TBI regimens | 25 | 1.00 | — | 12 | 1.00 | — | ||||
| TBI regimens | 285 | 0.72 (0.38-1.35) | .30 | — | 319 | 0.59 (0.27-1.26) | .17 | — | ||
| GVHD prophylaxis | ||||||||||
| Cyclosporine A with or without other | 283 | 1.00 | — | 171 | 1.00 | — | ||||
| Tacrolimus with or without other | 27 | 2.02 (1.15-3.56) | .01 | — | 160 | 1.38 (0.96-1.97) | .08 | — | ||
HR indicates hazard ratio; CI, confidence interval; WBC, white blood cell; —, not applicable; and TBI, total body irradiation.